Role of endocrine-immune dysregulation in osteoporosis, sarcopenia, frailty and fracture risk
- 30 June 2005
- journal article
- review article
- Published by Elsevier in Molecular Aspects of Medicine
- Vol. 26 (3) , 181-201
- https://doi.org/10.1016/j.mam.2005.01.004
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Gene expression changes accompanying p53 activity during estrogen treatment of osteoblastsLife Sciences, 2004
- Musculoskeletal agingCurrent Opinion in Rheumatology, 2004
- Epidemiology and outcomes of osteoporotic fracturesThe Lancet, 2002
- Androgens Suppress Osteoclast Formation Induced by RANKL and Macrophage-Colony Stimulating FactorEndocrinology, 2001
- Regulation of Collagenolytic Protease Secretion through c-Src in OsteoclastsBiochemical and Biophysical Research Communications, 2000
- CFU-GM-Derived Cells Form Osteoclasts at a Very High EfficiencyBiochemical and Biophysical Research Communications, 2000
- Estrogen Inhibits Phorbol Ester-Induced IκBα Transcription and Protein DegradationBiochemical and Biophysical Research Communications, 1998
- Estrogen modulation of avian osteoclast lysosomal gene expressionEndocrinology, 1993
- 'Senile' osteoporosis reconsideredJAMA, 1989
- Local and Systemic Factors in the Pathogenesis of OsteoporosisNew England Journal of Medicine, 1988